Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins

Molecular Pharmacology

Volumn 63, Issue 4, 2003, Pages 945-956

  Gouédard, Cédric ^a   Koum Besson, Nadine ^b   Barouki, Robert ^a   Morel, Yannick ^a,b  

^a INSERM   (France)

^b CENTRE D ETUDES DU BOUCHET   (France)

Author keywords

[No Author keywords available]

Indexed keywords

22 HYDROXYCHOLESTEROL; ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; FENOFIBRATE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; MESSENGER RNA; MEVALONIC ACID; ORGANOPHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOTRIESTERASE; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ARTICLE; CANCER CELL CULTURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVITY; GENE ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYDROLYSIS; HYPOLIPEMIA; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION;

ANTILIPEMIC AGENTS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; DNA; ESTERASES; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INDOLES; PRAVASTATIN; PROCETOFEN; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; SIMVASTATIN; TUMOR CELLS, CULTURED;

EID: 0344951233     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.4.945     Document Type: Article

References (40)

1. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, and La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Investig 101:1581-1590.
2. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, and Paragh G (2001) Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 27:604-610.
3. Beltowski J, Wojcicka G, Mydlarczyk M, and Jamroz A (2002) The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity and plasma paraoxonase 1 (PON 1) activity. J Physiol Pharmacol 53:463-475.
4. Billecke S, Draganov D, Counsell R, Stetson P, Watson C, Hsu C, and La Du BN (2000) Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 28:1335-1342.
5. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, and Furlong CE (2001) Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436.
6. Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, and Wrutniak-Cabello C (2000) New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett 482:71-74.
7. Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, and Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763-764.
8. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, and Bernini F (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84:413-428.
9. Cowan J, Sinton CM, Varley AW, Wians FH, Haley RW, and Munford RS (2001) Gene therapy to prevent organophosphate intoxication. Toxicol Appl Pharmacol 173:1-6.
10. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, and Furlong CE (1996) The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14:334-336.
11. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, and James RW (2001) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high-affinity, saturable, desorption mechanism. J Biol Chem 28:28.
12. Draganov DI, Stetson PL, Watson CE, Billecke SS, and La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435-33442.
13. Edgar AD, Tomkiewicz C, Costet P, Legendre C, Aggerbeck M, Bouguet J, Staels B, Guyomard C, Pineau T, and Barouki R (1998) Fenofibrate modifies transaminase gene expression via a peroxisome proliferator activated receptor alpha-dependent pathway. Toxicol Lett 98:13-23.
14. Feingold KR, Memon RA, Moser AH, and Grunfeld C (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307-315.
15. Forman BM, Ruan B, Chen J, Schroepfer GJ Jr, and Evans RM (1997) The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 94:10588-10593.
16. Furlong CE, Li WF, Richter RJ, Shih DM, Lusis AJ, Alleva E, and Costa LG (2000) Genetic and temporal determinants of pesticide sensitivity: role of paraoxonase (PON1). Neurotoxicology 21:91-100.
17. Jakubowski H (1999) Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 13:2277-2283.
18. Jakubowski H (2000) Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275:3957-3962.
19. Josse D, Xie W, Renault F, Rochu D, Schopfer LM, Masson P, and Lockridge O (1999) Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 38:2816-2825.
20. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, and Harmony JA (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33:832-839.
21. Krause BR and Princen HM (1998) Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice? Atherosclerosis 140:15-24.
22. Leviev I and James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516-521.
23. Li WF, Furlong CE, and Costa LG (1995) Paraoxonase protects against chlorpyrifos toxicity in mice. Toxicol Lett 76:219-226.
24. Lu TT, Repa JJ, and Mangelsdorf DJ (2001) Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism. J Biol Chem 276:37735-37738.
25. Luftjohann D, Sigit JI, Locatelli S, von Bergmann K, and Schmidt HH (2001) High-dose simvastin (80 mg/day) decreases plasma concentrations of total homocyst(e)ine in patients with hypercholesteromia. Atherosclerosis 155:265-266.
26. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, and Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457.
27. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, Najib-Fruchart J, Glineur C, and Staels B (2001) Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Investig 107:1423-1432.
28. Maynard R and Beswick F (1992) Organophosphorus compounds as chemical warfare agents, in Clinical and Experimental Toxicology of Organophosphates and Carbamates (Ballantyne B and Marrs TE eds), pp. 373-385, Oxford.
29. Morel Y and Barouki R (1998) Down-regulation of cytochrome P450 1A1 gene promoter by oxidative stress. Critical contribution of nuclear factor 1. J Biol Chem 273:26969-26976.
30. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, and Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444-44449.
31. Primo-Parmo SL, Sorenson RC, Teiber J, and La Du BN (1996) The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33:498-507.
32. Ray DE and Richards PG (2001) The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicol Lett 120:343-351.
33. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, and Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542-547.
34. Rodrigo L, Mackness B, Durrington PN, Hernandez A, and Mackness MI (2001) Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J 354:1-7.
35. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, et al. (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (Lond) 394:284-287.
36. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, and Fruchart JC (1998) Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093.
37. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, and Marrugat J (2000) Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 20:2113-2119.
38. Van Lenten BJ, Wagner AC, Navab M, and Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923-1929.
39. Vu-Dac N, Chopin-Delannoy S, Gervois P, Bonnelye E, Martin G, Fruchart JC, Laudet V, and Staels B (1998) The nuclear receptors peroxisome proliferator-activated receptor a and Rev-erba mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem 273:25713-25720.
40. Westphal S, Dierkes J, and Luley C (2001) Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 358:39-40.